1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Population-based study of patients with primary Sjögren’s syndrome and lymphoma : lymphoma subtypes, clinical characteristics, and gender differences
- Contribution to journal › Article
- 2019
-
Mark
Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren’s syndrome
- Contribution to journal › Article
- 2013
-
Mark
450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments
- Contribution to journal › Article
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
- Contribution to journal › Article
- 2011
-
Mark
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
- Contribution to journal › Letter
-
Mark
Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time
(2011) Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem In Biology of Blood and Marrow Transplantation 17(2). p.196-196
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
In mantle cell lymphoma (MCL) the MCL-International Prognostic Index (MIPI) is a better predictor of event-free and overall survival than International Prognostic Index (IPI) in patients receiving intensive 1st line treatment including ASCT
(2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0971-0971
- Contribution to journal › Published meeting abstract
-
Mark
Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group
(2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.1082-1082
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
The BCL-2 promoter (-938C > A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia
- Contribution to journal › Article
- 2006
-
Mark
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
- Contribution to journal › Article
